T1	p 173 238	patients with chronic heart failure after myocardial infarction .
T2	p 373 409	patients with heart failure ( HF ) .
T3	p 575 637	patients with class II to IV HF and ejection fraction < 35 % .
T4	p 1481 1566	HF patients with chronic postinfarction cardiomyopathy , transcatheter administration
T5	p 1570 1579	myoblasts
T6	p 1849 1895	HF patients with postinfarction cardiomyopathy
T7	i 127 148	myoblast implantation
T8	i 152 169	catheter delivery
T9	i 312 341	transcatheter intramyocardial
T10	i 360 369	myoblasts
T11	i 441 459	placebo-controlled
T12	i 469 554	image-guided , catheter-based intramyocardial injection of placebo or myoblasts ( 400
T13	i 558 561	800
T14	i 570 571	)
T15	i 994 1001	placebo
T16	i 1100 1110	amiodarone
T17	i 1164 1171	placebo
T18	i 1354 1361	placebo
T19	o 81 87	safety
T20	o 92 114	cardiovascular effects
T21	o 662 792	frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .
T22	o 947 964	numbers of events
T23	o 1053 1096	deaths . Ventricular tachycardia responsive
T24	o 1100 1110	amiodarone
T25	o 1245 1264	functional capacity
T26	o 1314 1318	walk
T27	o 1432 1465	Minnesota Living With HF scores .